Latest Breaking News On - Upluri - Page 1 : comparemela.com

Pluri (NASDAQ:PLUR) & Tenaya Therapeutics (NASDAQ:TNYA) Financial Review

Pluri (NASDAQ:PLUR – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Insider & Institutional Ownership 16.6% of Pluri shares […]

United statesSouth san franciscoPluri incTenaya therapeutics incPluristem therapeutics incGet free reportTenaya therapeuticsTenaya therapeuticGiven tenaya therapeuticPluristem therapeuticsPluri dailyNasdaq plurStock comparisonStock analysis

Breakthrough In Immune Cell Expansion: Pluri Granted U S Patent For New Method

Breakthrough In Immune Cell Expansion: Pluri Granted U S Patent For New Method
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Shachar yentalYaky yanayMadeline weirmanJessica daitchPluri incExchange commissionImmune cells expansionLarge scaleMore patientsPrivate securities litigation reform act

Breaking Barriers: Cultivated Meat Company Achieves Price Parity, Making Sustainable Eating Accessible

Fast forward a decade, and technology has advanced to the extent that meat grown by cultivating cells is ready to hit supermarket shelves.

Yaky yanayNir goldsteinGood food instituteAgriculture organisationWorld bankEver after foodsEver afterUpside foodsGood meatGood manufacturing practiceBreaking barriers cultivated meat company achieves price parityCultivated meatSustainable food

Pluri (NASDAQ:PLUR) & Ocugen (NASDAQ:OCGN) Head-To-Head Contrast

Pluri (NASDAQ:PLUR – Get Free Report) and Ocugen (NASDAQ:OCGN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Profitability This table compares Pluri and Ocugen’s net margins, […]

United statesPluri incPluristem therapeutics incCansino biologics incOcugen incGet free reportGiven ocugenPluristem therapeuticsCansino biologicsBharat biotechPluri dailyNasdaq plurStock comparisonStock analysis

Pluri (NASDAQ:PLUR) versus Graphite Bio (NASDAQ:GRPH) Financial Comparison

Pluri (NASDAQ:PLUR – Get Free Report) and Graphite Bio (NASDAQ:GRPH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent […]

South san franciscoUnited statesGraphite bio incPluristem therapeutics incPluri incMedicines incGet free reportGraphite bioGiven graphite bioPluristem therapeuticsIntegral medicinesPluri dailyNasdaq plurStock comparisonStock analysis